While the status quo, as it pertains to treatment of advanced prostate cancer, is persistent and potent AR inhibition, this work provides rationale to alternate between AR inhibition and activation with BAT to prolong the lives of patients with this disease. The gene discussed is AR; the disease is prostate cancer.